The financials
Edwards Lifesciences by the numbers
Edwards Lifesciences (EW) reported revenue of $1.74B in Q2 2026 (quarter ended June 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $241M (14% of revenue). For the full year FY2025, revenue was $6.07B (+12% year on year) and net income $1.07B. Its largest product in 2026-Q1 was Transcatheter Aortic Valve Replacement at $1.20B, 73% of the disclosed total, just ahead of Surgical at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.74B | $1.53B | +14% |
| Gross profit | $1.35B | $1.19B | +14% |
| Operating income | $513M | $411M | +25% |
| Net income | $241M | $332M | −27% |
| Diluted EPS | $0.42 | $0.56 | −25% |
| Product | Revenue | Share |
|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.20B | 73% |
| Surgical | $276M | 17% |
| Transcatheter Mitral And Tricuspid Therapies | $175M | 11% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.65B (+6.1%)
Transcatheter Mitral And Tricuspid Therapies grew +52% year on yearSurgical +10% year on year
Segment Latestquarter on quarteryear on year
- Transcatheter Aortic Valve Replacement$1.20B$1.20BQoQ +4.1%year on year +14%+4.1%+14%
- Surgical$276.2M$276.2MQoQ -year on year +10%-+10%
- Transcatheter Mitral And Tricuspid Therapies$175.1M$175.1MQoQ +21%year on year +52%+21%+52%
- Surgical Heart Valve Therapy--QoQ -year on year ---
Medical Devices
Ranks #18 of 35 by Smart Score